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Psoriasis is a T-cell-mediated immune dermatosis
probably triggered by bacterial superantigens. This
pathomechanism has been experimentally repro-
duced in a SCID-hu xenogeneic transplantation
model. We analyzed the effects of different bacterial
superantigens on the induction of psoriasis in this
model. Staphylococcal enterotoxin B and exfoliative
toxin triggered the onset of psoriasis when adminis-
tered repetitively intracutaneously over a period of 2
wk, whereas staphylococcal enterotoxin A represent-
ing a distinct subfamily of staphylococcal enterotox-
ins only mimicked certain aspects of psoriasis. The
biologic effects of staphylococcal enterotoxin A were
more pronounced when a mutated form, SEAH187A,
of this superantigen with reduced af®nity to major
histocompatibility complex class II was coinjected.
Another mutated variant, SEAF47A/D227A, exhibiting
no measurable major histocompatibility complex
class II af®nity blocked the effects triggered by wild-
type staphylococcal enterotoxin A when injected in a
10-fold higher dose. Inhibition was speci®c as induc-
tion of psoriasiform epidermal changes by staphylo-
coccal enterotoxin B could not be blocked. As
staphylococcal enterotoxin A, in contrast to the
other superantigens tested, is capable of inducing
epidermal thickening but not the typical appearance
of psoriasis, we conclude that bacterial superantigens
may differ with regard to their effects on human
nonlesional psoriatic skin. Staphylococcal-entero-
toxin-A-mediated effects were blocked by a genetic-
ally engineered superantigen highlighting the
potential therapeutic use of mutated superantigens.
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B
acterial superantigens (Acha-Orbea, 1995) are char-
acterized by their ability to interact with and activate T
cells that share de®ned T cell receptor Vb segments.
The portion of the T cell repertoire activated by any
given superantigen is several orders of magnitude
higher than activation by conventional antigen and lies in the range
of 10%. This response is not human leukocyte antigen (HLA)
restricted because superantigens associate with HLA class II
molecules outside the peptide binding groove. Different super-
antigens do exhibit distinct preferences regarding -DR, -DP and
-DQ isotypes, however (Herrmann et al, 1989; Mollick et al, 1991).
Among bacterial superantigens the staphylococcal enterotoxins
(SEs) (Svensson et al, 1997) are a family of structurally related
exotoxin molecules produced by certain Gram-positive
Staphylococcus aureus bacterial strains. Comparison of sequence
homologies allows division of the SEs into two subfamilies: SEB
and SEC1±3 have marked homology, forming one subfamily,
whereas SEA, SED, SEE, and SEH form a second subfamily.
TSST-1 is another superantigen secreted by S. aureus exhibiting
structural relationships to the SE family. Finally, approximately
5% of S. aureus strains secrete staphylococcal exfoliative toxins
(ETs), designated serotypes A and B. ETA, which is the
causative agent in staphylococcal scaled skin syndrome, functions
as serine protease, but also has superantigen properties (Vath et
al, 1997).
There is increasing evidence that superantigens are involved in
the pathogenesis of several autoimmune diseases, e.g., rheumatoid
arthritis (Paliard et al, 1991) and diabetes mellitus (Conrad et al,
1994). Another T-cell-mediated autoimmune disease is psoriasis.
Clinically, there is an association of this disease with bacterial
infections, an observation that led to the hypothesis of psoriasis
being triggered by superantigen-activated T cells cross-reacting
with keratins (Valdimarsson et al, 1995). Induction of psoriasis
could be demonstrated experimentally in the SCID-hu xenogeneic
transplantation model by injecting bacterial superantigens into
nonlesional psoriatic skin transplanted onto mice lacking functional
B and T cells (Boehncke et al, 1996). This phenomenon was found
to be T cell dependent (Wrone-Smith and Nickoloff, 1996).
Based on the potential of SEs to induce psoriasis we investigated
the possibility of interfering with this process by applying mutated
forms of the respective SEs. Here we demonstrate that a mutation
of F47 to A and D227 to A in SEA causing loss of major
histocompatibility complex (MHC) class II af®nity speci®cally
inhibits the effects triggered by wild-type SEA when injected in a
10-fold higher dose.
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MATERIALS AND METHODS
Patients This study was approved by the ethics committee of the
Faculty of Medicine of the Johann-Wolfgang-Goethe University,
Frankfurt. Written informed consent was obtained from nine patients
with chronic plaque-stage psoriasis and nonlesional skin was excised from
the inner aspect of the upper arm under local anesthesia.
Transplantation procedure The animal experiments were approved
by the RegierungspraÈsidium Darmstadt (II17a±19c 20/15±F 79/02).
Transplantations were done as described previously (Boehncke et al,
1994). Human full-thickness xenografts were transplanted onto the back
of 6±8-wk-old C.B17 SCID mice (Charles River, Sulzfeld, Germany).
For the surgical procedure, mice were anesthetized by intraperitoneal
injection of 100 mg per kg ketamine and 5 mg per kg xylazine. Spindle-
shaped pieces of full-thickness skin measuring 1 cm in diameter were
grafted onto corresponding excisional full-thickness defects of the shaved
central dorsum of the mice and ®xed by 6-0 atraumatic mono®lament
sutures. After applying a sterile Vaseline-impregnated gauze, the grafts
were protected from injury by suturing a skin pouch over the
transplanted area using the adjacent lateral skin. The sutures and over-
tied pouches were left in place until they resolved spontaneously after 2±
3 wk.
Treatment protocols Grafts were allowed 4 wk for acceptance and
healing onto the mice. Injections were performed on days 28, 31, 34,
and 37 after transplantation.
For analysis of the biologic effects of bacterial superantigens, 2 mg of
either ET (Toxin Technologies) or SEA or SEB (Active Biotech, Lund,
Sweden) representing different SE subfamilies were injected intradermally
in a ®nal volume of 200 ml. In parallel, 2 3 106 of the donors' peripheral
blood mononuclear cells (PBMC) were injected intraperitoneally in
100 ml phosphate-buffered saline (PBS). These cells were prepared from
peripheral blood taken at the time of skin excision by Ficoll density
gradient sedimentation (Sigma, Germany), frozen in medium containing
90% fetal bovine serum (FBS) and 10% dimethylsulfoxide, and stored at
±80°C. Forty-eight hours prior to injection the PBMC were thawed and
cultured at 37°C in an atmosphere containing 5% CO2. The medium
used was supplemented RPMI-1640 (Seromed, Berlin, Germany). Cells
were stimulated for the total period of 48 h with the corresponding
superantigens at a concentration of 100 ng per ml. PBS served as
negative control both in vitro and in vivo.
To assess the capability of mutant superantigens to block the effects
induced by wild-type superantigens the former were added to the cell
cultures in vitro 2 h prior to the latter and also injected into the
corresponding grafts at a 10-fold excess (1 mg per ml in vitro and 20 mg
in vivo, respectively).
In all experiments three grafts of three different donors underwent an
identical treatment protocol. Thus, the data presented are based on
®ndings of nine different grafts.
For the analysis of antibody production towards wild-type SEA and
SEAF47A/D227A two mice each were injected intraperitoneally with
PBMC stimulated by wild-type SEA either alone or in combination with
SEAF47A/D227A followed by intramuscular injections twice weekly for
2 wk. Serum was analyzed for the presence of anti-SEA antibodies in an
enzyme-linked immunosorbent assay.
In vitro mutagenesis and protein production In vitro mutagenesis of
genetically engineered SEA variants, protein expression, and puri®cation
were performed as described previously (Abrahmsen et al, 1995).
Analysis of the grafts Mice were sacri®ced at day 40 and following
excision with surrounding mouse skin the grafts were formalin-
embedded. Subsequently, routine hematoxylin and eosin stainings were
performed and the grafts were analyzed with regard to their pathologic
changes both qualitatively (epidermal differentiation, in¯ammatory
in®ltrate) and quantitatively (epidermal thickness) by a blinded
investigator as described previously (Boehncke et al, 1994). Brie¯y,
maximal epidermal thickness was measured from the tip of the rete
ridges to the border of the viable epidermis. The values were determined
using an ocular micrometer, taking the mean of 10 consecutively
measured rete ridges. The results were expressed as mean 6 standard
deviation in microns. Statistical analyses were performed using Graph
Pad Instat software and the paired nonparametric Kruskal±Wallis test
calculating one-tail p-values.
Antagonistic effects of SEAwt and SEAF47A/D227A in vitro
Cytotoxicity was measured in a 4 h 51Cr release assay (Rosendahl et al,
1999). An SEA-reactive human T cell line was used as effector cells and
was preincubated for 2 h with varying concentrations of SEAF47A/D227A.
SEAwt was added at varying concentrations together with
51Cr-labeled
human MHC class II expressing Raji cells. The mixtures were cultured
with 2500 target cells per 0.2 ml complete R-medium (RPMI 1640;
BioWhittaker, Verviers, Belgium) supplemented with 10% FBS
(HyCrone, Logan, UT), 5 3 10±5 M b-mercaptoethanol (Merck,
Darmstadt, Germany), and 0.1 mg per ml gentamycin (Biological
Industries, Beit Haemek, Israel) at an E:T ratio of 30:1. The percentage
of speci®c cytotoxicity was calculated as 100 3 (cpm experimental
release ± cpm background release)/(cpm total release ± cpm background
release).
RESULTS
Different staphylococcal superantigens exhibit distinct
effects in nonlesional psoriatic skin The biologic effects of
different bacterial superantigens were analyzed in nonlesional skin
grafts from three patients with chronic plaque-stage psoriasis.
ET has previously been shown to be capable of inducing
psoriasiform changes in nonlesional psoriatic skin grafted onto
SCID mice (Boehncke et al, 1996) and was therefore selected as
positive control. Repetitive intradermal injections with ET along
with intraperitoneal injections of autologous PBMC stimulated
in vitro with ET yielded statistically signi®cant akanthosis
(448 6 37 mm, p < 0.001, Fig 1, Table I) and papillomatosis
along with parakeratosis and reduction or even complete loss of the
granular layer. Moreover, a mononuclear in®ltrate occurred in the
upper dermis exhibiting some exocytosis, but Munro's micro-
abscesses were not detected (Table I, Fig 2c, d).
SEA and SEB were selected as representatives of the two major
SE subfamilies. Injections with SEA and SEA-activated PBMC
resulted in obvious akanthosis, which was signi®cantly less
pronounced compared with ET (p < 0.01, Fig 1, Table I).
Papillomatosis was not seen, but parakeratosis was a constant
feature. Munro's microabscesses were occasionally seen (Table I,
Fig 2e, f). SEB effects were characterized by induction of a more
pronounced akanthosis and papillomatosis compared with SEA and
an in¯ammatory in®ltrate characterized by the frequent occurrence
of Munro's microabscesses (Table I, Figs 1, 2g, 2h). Both SEA
and SEB caused comparable reduction of the granular layer.
Mutations in the HLA class-II binding site of SEA modulate
the in vivo activity of SEA In order to interfere with the
biologic effects exhibited by the superantigens included in this
study mutations of wild- type SEA were generated and tested in
nonlesional skin grafts derived from three patients suffering from
Figure 1. Epidermal thickness of human nonlesional psoriatic
skin transplanted onto SCID mice. The line marks the mean. ET
and SEB induce statistically signi®cant akanthosis, whereas SEA induces
signi®cantly less epidermal thickening compared with ET (p < 0.01).
VOL. 116, NO. 4 APRIL 2001 ANTAGONISTIC EFFECTS OF MUTANT SEA IN THE SCID-HU MODEL 597
chronic plaque-stage psoriasis (not identical with the patients in the
®rst set of experiments).
Alanine substitution of a histidine at position 187 in SEA
(SEAH187A) results in an approximately 10-fold reduction in af®nity
towards MHC class II (Abrahmsen et al, 1995). This mutant is able
to induce some akanthosis when injected at doses of 20 mg into
nonlesional psoriatic skin (Table II). Combination with SEAwt
resulted in an additive effect with respect to akanthosis (Fig 3).
Moreover, papillomatosis was noted (Table II, Fig 4a, b). This
feature is not easily explained as an additive effect as the effect was
not present in grafts treated with either SEAwt or SEAH187A alone.
Another mutated peptide designated SEAF47A/D227A exhibiting
no measurable MHC class II af®nity did not exhibit any effects at
doses of 20 mg on nonlesional psoriatic skin (Table II, Figs 3,
4c, 4d). Most interestingly it was capable of inhibiting the effects of
SEAwt: grafts pretreated with 20 mg SEAF47A/D227A and subse-
Figure 2. Macroscopic and histologic
appearance of human nonlesional psoriatic
skin transplanted onto SCID mice. PBS-
treated controls remain largely unaltered (a, b),
whereas grafts receiving wild-type SEs show
different degrees of psoriasiform transformation.
ET-treated grafts appear thicker and erythematous
(c); histologically akanthosis, papillomatosis, and
orthokeratosis along with an exocytotic in®ltrate
are observed (d). SEA-treated grafts lack
papillomatosis (e, f), whereas grafts challenged with
SEB (g, h) frequently exhibit Munro's micro-
abscesses.
Table I. Biologic effects of several staphylococcal superantigens on human nonlesional psoriatic skin
Protocol Epidermal thicknessa Papillomatosis Keratinization In®ltrate Comments
PBS 167 6 25 ± orthokeratosis sparse negative control
ET 448 6 37* ++ parakeratosis intermediate positive control loss of granular layer
SEA 285 6 27** ± parakeratosis intermediate occasionally Munro's reduction of granular layer microabscesses
SEB 355 6 32*** ++ parakeratosis dense frequently Munro's reduction of granular layer microabscesses
aMean and standard deviation in mm; *p < 0.001 versus PBS; **p < 0.01 versus ET; ***p < 0.01 versus PBS.
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quently challenged with SEAwt at a dose of 2 mg were characterized
by only minimal akanthosis; the degree of akanthosis was
signi®cantly reduced compared to grafts receiving SEAwt along
with the nonblocking mutant SEAH187A (p < 0.01). Signs of
abnormal keratinization were also minimal, usually a granular layer
was established, and the corneal layer frequently exhibited the
normal web-like structure (Table II, Fig 4e, f). Thus, SEAF47A/
D227A seems to exhibit antagonistic effects on SEAwt in this model.
These differences between grafts treated with SEA in the
presence or absence of SEAH187A or SEAF47A/D227A were visible
already macroscopically: SEAwt-treated grafts appeared thicker and
erythematous compared with PBS-treated controls (Fig 2a, b versus
Fig 2e, f). These changes were more pronounced when SEAwt and
SEAH187A were coadministered (Fig 4a, b). In contrast, grafts
treated with wild-type SEAwt and SEAF47A/D227A appeared to be
only slightly thicker and more erythematous than PBS-treated
controls (Fig 4e, f).
The antagonistic effect of SEAF47A/D227A is not due to
antibody formation A possible explanation for the blocking
effect of SEAF47A/D227A could be the induction of neutralizing
human anti-SEA antibodies. To test this possibility two mice each
were injected intraperitoneally with PBMC stimulated by SEAwt
either alone or in combination with SEAF47A/D227A followed by
intramuscular injections twice weekly for 2 wk. The presence of
human anti-SEA antibodies was below the limit of detection for the
assay (i.e., 0.8 mg per ml) in all samples.
The antagonistic effect of SEAF47A/D227A is speci®c In order
to test whether SEAF47A/D227A might represent a more general
superantigen inhibitor nonlesional skin grafts from three psoriatic
patients (not identical with those in the ®rst two sets of
experiments) were pretreated with SEAF47A/D227A and then
challenged with SEBwt. In these experiments the phenotype
induced by SEBwt alone characterized by extensive akanthosis
and papillomatosis could not be altered (Table II, Figs 3, 4g, 4h).
Thus, SEAF47A/D227A seems to be capable of speci®cally interfering
with the effects of SEA in vivo.
SEAF47A/D227A inhibits SEAwt-mediated effects in vitro In
order to analyze in vitro inhibition of SEAwt-mediated effects of
SEAF47A/D227A cytotoxicity assays were performed using an SEA-
reactive cytotoxic human T cell line as effector cells together with
51Cr-labeled human HLA class II expressing Raji cells. Incubation
with SEAwt resulted in >50% cytotoxicity at concentrations >10
±12
M, whereas no measurable cytotoxicity occurred with
SEAF47A/D227A at concentrations up to 10
±9 M (Fig 5). Pre-
incubation of Raji cells with SEAF47A/D227A and subsequent
addition of SEAwt resulted in a dose-dependent reduction of
cytotoxicity (Fig 5) thus documenting the in vitro inhibitory
ef®cacy of SEAF47A/D227A.
DISCUSSION
Using the SCID-hu xenogeneic transplantation model it was
possible to directly demonstrate induction of psoriasis by bacterial
superantigens (Boehncke et al, 1996; Wrone-Smith and Nickoloff,
1996). Here we highlight the possibility of speci®cally interfering
with this process by applying mutant forms of the respective wild-
type superantigen.
The SCID-hu xenogeneic transplantation system is now a widely
accepted model for studying the pathophysiology of complex
human diseases in general (Boehncke, 1999) and of psoriasis in
particular (SchoÈn, 1999). Recently the suitability of the model for
the screening of potential antipsoriatic treatments was demonstrated
(Boehncke et al, 1999; Dam et al, 1999). Therefore, this system was
chosen to analyze the biologic effects of superantigens in human
skin.
Regarding the biologic effects of bacterial superantigens two
scenarios are possible: the effects seen either could be intrinsic
properties of the respective superantigens, or they could depend on
the environment. The former point of view is supported by
evidence for the involvement of staphylococcal superantigens in the
pathogenesis of atopic dermatitis (Leung, 1997), whereas strepto-
coccal superantigens are thought to be more relevant for the
pathogenesis of psoriasis (Valdimarsson et al, 1995). Whether this
association is indeed so strict is still a matter of debate, as at least
with reference to psoriasis reports on the presence of a T cell
in®ltrate primarily responsive to streptococcal superantigens (Baker
et al, 1995; Leung et al, 1995) stand beside ®ndings documenting T
Table II. Biologic effects of two genetically engineered SEA variants on human nonlesional psoriatic skin
Protocol Epidermal thicknessa Papillomatosis Keratinization In®ltrate Macroscopic appearance
SEAH187A 250 6 29 ± orthokeratosis sparse largely unaltered
SEAF47A/D227A 157 6 48 ± orthokeratosis sparse largely unaltered
SEAwt + SEAH187A 291 6 29* + parakeratosis dense thickened, erythematous
SEAwt + SEAF47A/D227A 182 6 31** ± orthokeratosis moderate slightly thickened and erythematous
SEBwt + SEAF47A/D227A 313 6 32*** ++ parakeratosis dense profound thickening intermediate erythema
aMean and standard deviation in mm; *p < 0.001 versus SEAF47A/D227A; **p < 0.01 versus SEAwt + SEAH187A; ***p < 0.001 versus SEAwt + SEAF47A/D227 and p < 0.001
versus SEAF47A/D227A.
Figure 3. Epidermal thickness of human nonlesional psoriatic
skin transplanted onto SCID mice. The line marks the mean. The
SEA mutant SEAF47A/D227A blocks induction of akanthosis by the wild-
type SEA signi®cantly (p < 0.01), whereas epidermal thickening induced
by SEB is not affected by this protein.
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cells reacting towards staphylococcal superantigens (Bour et al,
1995; Yokote et al, 1995). Moreover, in the SCID-hu model
applied also in this study we and others were able to demonstrate
inducibility of psoriasis by staphylococcal superantigens (Boehncke
et al, 1996; Wrone-Smith and Nickoloff, 1996). The latter reports
also document lack of induction of in¯ammatory alterations in
grafts derived from normal human skin by the respective super-
antigens. Thus, superantigens alone are not suf®cient to trigger
psoriasis, and the ``source'' of the graft has an impact on their
effects. In this report we observed that superantigens representing
distinct SE subfamilies differ with regard to their effects on grafts
derived from nonlesional skin of psoriatic patients, although they all
caused changes that resembled each other. Therefore we think that
a predisposition intrinsic to the skin compartment is needed in
order to induce psoriasis in nonlesional skin. On the other hand the
``psoriatrogenic'' ef®cacy of distinct SEs differs markedly.
Superantigens seem to play a crucial role in the development of
T-cell-mediated autoimmunity. Although potentially autoreactive
T cells are eliminated in the thymus by means of negative selection/
depletion a small fraction of those cells can still be found, but the
respective cells are in the state of anergy (Nossal, 1994). Anergy can
be broken when both the suitable autoantigen and a costimulatory
signal are present simultaneously. This cascade of events can be
demonstrated in animal models using a bacterial superantigen as
stimulus (Brocke et al, 1993). Besides psoriasis (Valdimarsson et al,
1995; Boehncke, 1996), there is evidence for the involvement of
Figure 4. Effects of genetically engineered
SEA variants on human nonlesional psoriatic
skin treated with wild-type SEs. SEAwt and
SEAH187A exhibit additive effects and also show
papillomatosis (a, b). SEAF47A/D227A alone does
not alter the grafts (c, d) but is capable of blocking
SEAwt-mediated transformations (e, f). Changes
induced by SEBwt, however, are not affected
(g, h).
Figure 5. The ability of SEAF47A/D227A to inhibit SEA-dependent
cellular cytotoxicity against MHC class II+ Raji cells was analyzed
in a 4 h 51Cr release assay. SEA-stimulated human T cell line was
used as effector cells. Data from one of three representative experiments
are shown.
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superantigens also in other human diseases (Paliard et al, 1991;
Conrad et al, 1994). It is therefore intriguing to speculate about the
possibility of interfering with the superantigen-mediated induction
of autoimmunity. In this report we were able to demonstrate
interference with the SEA-mediated induction of psoriasis by
means of a mutated form of the respective superantigen. As
SEAF47A/D227A lacks measurable MHC class II af®nity the
inhibitory effect on SEAwt could be due to competition for
available T cell receptor Vb elements. Alternatively, binding of the
nonfunctional SEAF47A/D227A mutant could result in a nonactivat-
ing downregulation of the T cell receptor (Valltutti et al, 1995).
Given the distinct repertoire of T cell receptor Vb elements
recognized by any given SE, we interpret the speci®city of the
inhibition of SEAF47A/D227A, which blocks effects in nonlesional
psoriatic skin mediated by SEAwt but not SEBwt, as further
evidence for SEAF47A/D227A acting at the level of the T cell
receptor. The possibility of induction of anti-SEA antibodies by the
mutated SEAF47A/D227A was ruled out, as no such antibodies could
be detected in the sera of the mice.
In the ®eld of oncology, SEA application for therapeutic
purposes has already been undertaken in the form of fusion
proteins composed of a tumor-reactive monoclonal antibody and
the superantigen (Giantonio et al, 1997; GidloÈf et al, 1997; Hansson
et al, 1997). Here, too, alteration of MHC class II af®nity was
necessary to yield a practical therapeutic tool: reducing the MHC
class II af®nity of SEA resulted in reduced systemic immune
activation and thus toxicity of this approach (Hansson et al, 1997).
For psoriasis, two possible ± highly speculative at this point in time,
however ± clinical applications could be imagined. Frequently, a
new rash of an already established psoriasis is triggered by infections
with superantigen-producing bacteria; these infections precede the
rash by several weeks. Identi®cation of the relevant superantigen
and subsequent vaccination with a mutated form of the respective
superantigen might prevent the rash. A prophylactic vaccination
with genetically engineered superantigens of patients at risk of
developing psoriasis would be even more bene®cial. Right now, at
least the population at risk of developing psoriasis could principally
be de®ned in part: people with a positive family history exhibiting
certain HLA class II genotypes have a dramatically higher risk of
developing psoriasis (Christophers and Henseler, 1989; Tomfohrde
et al, 1994; Burden et al, 1998). Application of this potential
vaccination strategy would be limited, however, to those cases of
psoriasis where the disease or the respective rash is triggered by
infection with superantigen-producing bacteria. The remainder of
the patients would not be expected to bene®t from this approach.
In summary, this report documents differences regarding the
``psoriatrogenic'' ef®cacy of SEs representing distinct subfamilies in
nonlesional psoriatic skin. Triggering psoriasis in this system can
speci®cally be blocked by a mutant SE lacking measurable MHC
class II binding af®nity, thus indicating the potential therapeutic use
of altered bacterial superantigens.
W-HB is supported by grant Bo 895/9±1 of the Deutsche Forschungsgemeinschaft.
REFERENCES
Abrahmsen L, Dohlsten M, Segren S, Bjork P, Jonsson E, Kalland T:
Characterization of two distinct MHC class II binding sites of the
superantigen staphylococcal enterotoxin A. EMBO J 14:2978±2986, 1995
Acha-Orbea H: Superantigens and tolerance. In Bell JI, Owen MJ, Simpson E, eds. T
Cell Receptors. Oxford: Oxford University Press, 1995, pp 224±265
Baker BS, Bokth S, Powles A, Garioch JJ, Lewis H, Valdimarsson H, Fry L: Group A
streptococcal antigen-speci®c T lymphocytes in guttate psoriatic lesions. Br J
Dermatol 128:493±499, 1995
Boehncke W-H: Psoriasis and bacterial superantigens ± formal or causal correlation?
Trends Microbiol 4:485±489, 1996
Boehncke W-H: The SCID-hu xenogeneic transplantation model: complex but
telling. Arch Dermatol Res 291:367±373, 1999
Boehncke W-H, Sterry W, Hainzl A, Scheffold W, Kaufmann R: Psoriasiform
architecture of murine epidermis overlying human psoriatic dermis transplanted
onto SCID mice. Arch Dermatol Res 286:325±330, 1994
Boehncke W-H, Dressel D, Zollner TM, Kaufmann R: Pulling the trigger on
psoriasis. Nature 379:777, 1996
Boehncke W-H, Kock M, Hardt-Weinelt K, Wolter M, Kaufmann R: The SCID-
hu xenogeneic transplantation model allows screening of anti-psoriatic drugs.
Arch Dermatol Res 291:104±106, 1999
Bour H, Demidem A, Garrigue J-L, Krasteva M, Schmitt D, Claudy A, Nicolas J-F:
In vitro T cell response to staphylococcal enterotoxin B superantigen in chronic
plaque type psoriasis. Acta Derm Venerol 75:218±221, 1995
Brocke S, Gaur A, Piercy C, Gautam A, Fathman CG, Steinman L: Induction of
elapsing paralysis in experimental allergic encephalomyelitis by bacterial
superantigen. Nature 365:642±644, 1993
Burden AD, Javed S, Bailey M, Hodgins M, Connor M, Tillman D: Genetics of
psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol
110:958±960, 1998
Christophers E, Henseler T: Patient subgroups and the in¯ammatory pattern in
psoriasis. Acta Derm Venerol 69 (Suppl. 151):88±92, 1989
Conrad B, Weldmann E, Trucco G, et al: Evidence for superantigen involvement in
insulin-dependent diabetes mellitus aetiology. Nature 371:351±355, 1994
Dam TN, Kang S, Nickoloff BJ, Voorhees JJ: 1a,25-dihydroxycholecalciferol and
cyclosporine suppress induction and promote resolution of psoriasis in human
skin grafts transplanted on to SCID mice. J Invest Dermatol 113:1082±1089,
1999
Giantonio BJ, Alpaugh RK, Schultz J, et al: Superantigen-based immunotherapy: a
phase I trial of PNU-214565, a monoclonal antibody-staphylococcal
enterotoxin A recombinant fusion protein, in advanced pancreatic and
colorectal cancer. J Clin Oncol 15:1994±2007, 1997
GidloÈ f C, Dohlsten M, Lando P, Kalland T, SundstroÈm C, ToÈtterman TH: A
superantigen±antibody fusion protein for T-cell immunotherapy of human B-
lineage malignancies. Blood 89:2089±2097, 1997
Hansson J, Ohlsson L, Persson R, et al: Genetically engineered superantigens as
tolerable antitumor agents. Proc Natl Acad Sci (USA) 94:2489±2494, 1997
Herrmann T, Accolla RS, MacDonald HR: Different staphylococcal enterotoxins
bind preferentially to distinct major histocompatibility complex class II
isotypes. Eur J Immunol 19:2171±2174, 1989
Leung DYM: Atopic dermatitis: immunobiology and treatment with immune
modulators. Clin Exp Immunol 107 (Suppl. 1):25±30, 1997
Leung DYM, Travers JB, Giorno R, et al: Evidence for a streptococcal superantigen-
driven process in acute guttate psoriasis. J Clin Invest 96:2106±2112, 1995
Mollick JA, Chintagumpala M, Cook RG, Rich RR: Staphylococcal exotoxin
activation of T cells. Role of exotoxin-MHC class II binding af®nity and class
II isotypes. J Immunol 146:463±468, 1991
Nossal GJV: Negative selection of lymphocytes. Cell 76:229±239, 1994
Paliard X, West SG, Lafferty JA, Clements JR, Kappler JW, Marrack P, Kotzin BL:
Evidence for the effects of a superantigen in rheumatoid arthritis. Science
253:325±329, 1991
Rosendahl A, Kristensson K, Riesbeck K, Dohlsten M: T cell cytotoxicity assays for
studying the functional interaction between the superantigen SEA and TCR. In:
Holst O, ed. Bacterial Toxins Methods and Protocols. Totowa: Humana Press, 1999.
SchoÈn MP: Animal models of psoriasis ± what can we learn from them? J Invest
Dermatol 112:405±410, 1999
Svensson LA, Schad EM, SundstroÈm M, Antonsson P, Kalland T, Dohlsten M:
Staphylococcal enterotoxins A, D, and E. Structure and function, incuding
mechanism of T-cell superantigenicity. In Leung DYM, Huber BT, Schlievert
PM, eds. Superantigens Molecular Biology, Immunology, and Relevance to Human
Disease. New York: Marcel Dekker, 1997, pp 199±229
Tomfohrde J, Silverman A, Barnes R, et al: Gene for familial psoriasis susceptibility
mapped to the distal end of human chromosome 17q. Science 264:1141±1145,
1994
Valdimarsson H, Baker BS, Jonsdottir I, Powles A, Fry L: Psoriasis: a T-cell mediated
autoimmune disease induced by streptococcal superantigens? Immunol Today
16:145±149, 1995
Valltutti S, MuÈller S, Cella M, Padovan E, Lanzavecchia A: Serial triggering of many
T-cell receptors by a few peptide-MHC complexes. Nature 375:148±151, 1995
Vath GM, Earhart CA, Rago JV, Kim MH, Bohach GA, Schlievert PM, Ohlendorf
DH: The structure of the superantigen exfoliative toxin A suggests a novel
regulation as a serine protease. Biochemistry 36:1559±1566, 1997
Wrone-Smith T, Nickoloff BJ: Dermal injection of immunocytes induces psoriasis. J
Clin Invest 98:1878±1887, 1996
Yokote R, Tokura Y, Furukawa F, Takigawa M: Susceptible responsiveness to
bacterial superantigens in peripheral blood mononuclear cells from patients
with psoriasis. Arch Dermatol Res 287:443±447, 1995
VOL. 116, NO. 4 APRIL 2001 ANTAGONISTIC EFFECTS OF MUTANT SEA IN THE SCID-HU MODEL 601
